193 related articles for article (PubMed ID: 35301645)
21. Craniopharyngioma-An update on metabolic and cognitive complications and new therapy.
Erfurth EM
J Intern Med; 2023 Sep; 294(3):269-280. PubMed ID: 37424210
[TBL] [Abstract][Full Text] [Related]
22. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
Hengartner AC; Prince E; Vijmasi T; Hankinson TC
Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
[TBL] [Abstract][Full Text] [Related]
23. Targeted Therapy in the Management of Modern Craniopharyngiomas.
Reyes M; Taghvaei M; Yu S; Sathe A; Collopy S; Prashant GN; Evans JJ; Karsy M
Front Biosci (Landmark Ed); 2022 Apr; 27(4):136. PubMed ID: 35468695
[TBL] [Abstract][Full Text] [Related]
24. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
[TBL] [Abstract][Full Text] [Related]
25. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
[TBL] [Abstract][Full Text] [Related]
26. The molecular pathogenesis of craniopharyngiomas.
Campanini ML; Almeida JP; Martins CS; de Castro M
Arch Endocrinol Metab; 2023 Mar; 67(2):266-275. PubMed ID: 36748936
[TBL] [Abstract][Full Text] [Related]
27. Subtype-dependent difference of glucose transporter 1 and hexokinase II expression in craniopharyngioma: an immunohistochemical study.
Mukada N; Tosaka M; Matsumura N; Yamaguchi R; Aihara M; Isoda K; Higuchi T; Tsushima Y; Yokoo H; Yoshimoto Y
Sci Rep; 2021 Jan; 11(1):126. PubMed ID: 33420213
[TBL] [Abstract][Full Text] [Related]
28. Medical Therapy for Craniopharyngiomas.
Alexandraki KI; Xekouki P
touchREV Endocrinol; 2021 Nov; 17(2):121-132. PubMed ID: 35118458
[TBL] [Abstract][Full Text] [Related]
29. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Robinson LC; Santagata S; Hankinson TC
Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
[TBL] [Abstract][Full Text] [Related]
30. The Wnt signalling cascade and the adherens junction complex in craniopharyngioma tumorigenesis.
Preda V; Larkin SJ; Karavitaki N; Ansorge O; Grossman AB
Endocr Pathol; 2015 Mar; 26(1):1-8. PubMed ID: 25355426
[TBL] [Abstract][Full Text] [Related]
31. Contemporary Biological Insights and Clinical Management of Craniopharyngioma.
Apps JR; Muller HL; Hankinson TC; Yock TI; Martinez-Barbera JP
Endocr Rev; 2023 May; 44(3):518-538. PubMed ID: 36574377
[TBL] [Abstract][Full Text] [Related]
32. Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.
Rostami E; Witt Nyström P; Libard S; Wikström J; Casar-Borota O; Gudjonsson O
Acta Neurochir (Wien); 2017 Nov; 159(11):2217-2221. PubMed ID: 28918496
[TBL] [Abstract][Full Text] [Related]
33. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
Brastianos PK; Santagata S
Eur J Endocrinol; 2016 Apr; 174(4):R139-44. PubMed ID: 26563980
[TBL] [Abstract][Full Text] [Related]
34. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
35. Can tissue biomarkers reliably predict the biological behavior of craniopharyngiomas? A comprehensive overview.
Prieto R; Pascual JM
Pituitary; 2018 Aug; 21(4):431-442. PubMed ID: 29700680
[TBL] [Abstract][Full Text] [Related]
36. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas.
Brastianos PK; Taylor-Weiner A; Manley PE; Jones RT; Dias-Santagata D; Thorner AR; Lawrence MS; Rodriguez FJ; Bernardo LA; Schubert L; Sunkavalli A; Shillingford N; Calicchio ML; Lidov HG; Taha H; Martinez-Lage M; Santi M; Storm PB; Lee JY; Palmer JN; Adappa ND; Scott RM; Dunn IF; Laws ER; Stewart C; Ligon KL; Hoang MP; Van Hummelen P; Hahn WC; Louis DN; Resnick AC; Kieran MW; Getz G; Santagata S
Nat Genet; 2014 Feb; 46(2):161-5. PubMed ID: 24413733
[TBL] [Abstract][Full Text] [Related]
37. Craniopharyngioma: a roadmap for scientific translation.
Gupta S; Bi WL; Giantini Larsen A; Al-Abdulmohsen S; Abedalthagafi M; Dunn IF
Neurosurg Focus; 2018 Jun; 44(6):E12. PubMed ID: 29852761
[TBL] [Abstract][Full Text] [Related]
38. Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.
Khaddour K; Chicoine MR; Huang J; Dahiya S; Ansstas G
J Natl Compr Canc Netw; 2020 Dec; 18(12):1590-1595. PubMed ID: 33285519
[TBL] [Abstract][Full Text] [Related]
39. 60 YEARS OF NEUROENDOCRINOLOGY: Biology of human craniopharyngioma: lessons from mouse models.
Martinez-Barbera JP
J Endocrinol; 2015 Aug; 226(2):T161-72. PubMed ID: 25926515
[TBL] [Abstract][Full Text] [Related]
40. [Molecularly Targeted Therapy for Craniopharyngioma].
Tanaka S; Takayanagi S; Takami H; Saito N
No Shinkei Geka; 2022 Jan; 50(1):171-178. PubMed ID: 35169097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
